Ipamorelin

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide, meaning it's built from a chain of five amino acids, developed as part of a broader effort to find growth hormone secretagogues, compounds that trigger the pituitary gland to release growth hormone. It works through the same receptor as ghrelin, the body's natural hunger hormone, which is why it's classified in the ghrelin receptor agonist family.

What set ipamorelin apart when it was first characterized was its selectivity. Earlier compounds in its class tended to raise other hormones like cortisol and prolactin along with growth hormone, but research found ipamorelin stimulated growth hormone release without those side effects at comparable doses.^[1]

What Ipamorelin Is Being Researched For

• Selective Growth Hormone Release

  The defining area of ipamorelin research is its ability to stimulate growth hormone release while leaving other pituitary hormones, including cortisol, prolactin, and ACTH, largely unaffected.^[1]

• Pharmacokinetics and Dosing Patterns

  A dedicated human trial characterized how ipamorelin behaves in the body over time, mapping out its absorption, clearance, and the timing of the growth hormone response it triggers.^[2]

• Comparative Research Within Its Drug Class

  Because ipamorelin sits alongside other growth hormone secretagogues developed over several decades, researchers have reviewed how it compares mechanistically and in selectivity to earlier compounds in the same family.^[3]

How Ipamorelin Works

• Activating the Ghrelin Receptor

  Research points to ipamorelin binding to the growth hormone secretagogue receptor, the same receptor ghrelin naturally activates, which triggers a signaling cascade in the pituitary gland leading to growth hormone release.^[1]

• A Single, Time-Limited Release Pattern

  Research points to ipamorelin producing one distinct pulse of growth hormone release rather than a sustained elevation. Human studies found the growth hormone response peaked around 40 minutes after administration and then declined, mirroring the body's own natural pulsatile release pattern.^[2]

• Avoiding Broader Hormonal Effects

  Research points to ipamorelin's structure allowing it to trigger growth hormone release through the ghrelin receptor pathway without significantly activating the signaling that raises cortisol and prolactin in related compounds, which is the basis for its reputation as a more selective option in its class.^[1]

Reconstitution and Handling

Ipamorelin is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Ipamorelin's defining feature in the research literature is selectivity, triggering growth hormone release through the ghrelin receptor pathway without the broader hormonal effects seen in earlier compounds in its class. Its research base includes both the original selectivity findings and a dedicated human pharmacokinetic study mapping its behavior over time. It remains a research compound without an approved therapeutic indication.

Frequently Asked Questions

Sources and Research

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
2. Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharm Res. 1999;16(9):1412-1416.
3. Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37.